The fight against metastatic cancer—when malignant cells spread from the original tumour to distant organs—has long challenged physicians due to the difficulty of accurately locating secondary tumours. Typically, oncologists rely on the meticulous examination of lymph nodes, where metastasised cells frequently lodge, guiding surgical decisions and therapeutic plans. Current clinical methods involve radioactive tracers or blue dyes to mark these nodes, but both have significant limitations including safety concerns and allergic reactions. Warwick’s diamond sensor offers a promising alternative that is non-toxic, non-radioactive, and ultra-sensitive.

This device represents a remarkable leap forward in sensor miniaturization combined with quantum technology. The sensor head measures a mere 10 millimeters and contains an ultra-small diamond, only 0.5 cubic millimeters in volume, equipped with nitrogen vacancy centres. These NV centres act as highly sensitive magnetic field detectors, able to sense the minute fields produced by iron oxide nanoparticles within the magnetic tracer fluid introduced into the body. A small permanent magnet coupled to the probe introduces a stable magnetic bias, which, in conjunction with the diamond, enhances the detection capability while keeping the overall footprint compact.

The diamond sensor operates by detecting the magnetic signature of the tracer fluid after it is injected directly into the tumour site. This ferrofluid then travels naturally through the lymphatic system alongside the metastatic cancer cells. By sensing the precise magnetic fields emanating from these nanoparticles, surgeons can accurately locate sentinel lymph nodes that are critical to remove during breast cancer surgery to prevent further spread. Such real-time intraoperative guidance could drastically improve surgical outcomes and reduce unnecessary tissue removal.

The fundamental innovation lies in the quantum sensing capabilities of NV centres within the diamond lattice. These vacancies, consisting of a nitrogen atom adjacent to a lattice vacancy, possess a spin state that can be optically initialized and read out, enabling the measurement of magnetic fields with exceptional sensitivity and spatial resolution. This quantum metrology technique surpasses traditional magnetometers by providing localized, high-fidelity data without the need for bulky cooling systems or complicated electronics.

What makes this advancement particularly exciting is its usability in minimally invasive procedures. The sensor’s compact size allows it to be integrated into endoscopic tools, facilitating keyhole surgeries where accessibility is limited. Unlike conventional bulky magnetometers that are impractical in such settings, the diamond-based sensor provides surgeons with a practical tool for real-time magnetic tracing, enhancing precision without increasing procedural complexity.

Clinical translation has also been a core consideration throughout the device’s development. The team collaborated closely with breast cancer surgeons to ensure the technology meets the demands of actual surgical workflows. Notably, magnetic tracers have been increasingly adopted as a safer alternative to radioactive substances, gaining traction in numerous hospitals worldwide. However, current magnetic detection systems remain large or lack sufficient sensitivity. Warwick’s device addresses these limitations by delivering both portability and heightened sensitivity, capable of detecting just one-hundredth of a full clinical dose of magnetic tracer.

Beyond oncology, the team’s vision extends to broader applications of these diamond-based magnetometers. Quantum sensors utilizing NV centres have the potential to detect subtle magnetic phenomena in fusion reactors or even in the harsh environment of space exploration, where remote and robust sensing are paramount. This versatility underscores the transformative potential of integrating quantum materials into applied physics and medical technologies.

Traditional metastatic detection methods face notable drawbacks: radioactive tracers require stringent handling protocols and are unavailable in some clinical settings, while blue dyes carry risks of allergic reactions in a small percentage of patients. The diamond sensor’s approach circumvents these issues by eschewing radioactivity and toxic dyes altogether, offering a safer, more widely deployable alternative. Such a non-invasive and precise tool is poised to benefit patient safety and comfort tremendously.

Technologically, this ultra-sensitive magnetometer exemplifies the convergence of quantum physics, materials science, and biomedical engineering. Employing a diamond host for NV centres takes advantage of diamond’s remarkable optical transparency, thermal conductivity, and chemical inertness, which together facilitate stable and long-lived quantum sensing under room-temperature conditions. The integration of this sensor into a handheld device capable of clinical use marks a significant step toward real-world quantum-enabled diagnostics.

Stuart Robertson, a Consultant Breast Cancer Surgeon closely involved in the research, highlighted the clinical implications: “Magnetic localisation is becoming a valuable technique for detecting impalpable breast lesions and lymph nodes. Collaborating with Warwick to refine this magnetic technology promises to optimize surgical accuracy and patient outcomes.” Such endorsements from clinical practitioners reflect growing confidence in quantum sensing technologies for everyday medical applications.

As magnetic tracer fluids gain popularity for tumour localization, this diamond-based sensor represents the next frontier in surgical navigation. The authors suggest that the platform could be adapted to other cancers, like those affecting the lungs, liver, colon, and oesophagus, where precise detection of metastatic spread remains critical. Adoption of this sensor could usher in a new era of minimally invasive, quantum-enhanced cancer diagnostics that dramatically improve survival rates.

This study, recently published in Physical Review Applied, illustrates how fundamental research on quantum defects in diamonds is being translated into practical, life-saving innovations. By detecting magnetic nanoparticles at ranges and sensitivities previously unattainable with such small instruments, Warwick’s diamond magnetometer embodies the promise of converging physics and medicine. The next steps include clinical trials and refinement for broader surgical integration, aiming to bring this quantum technology into operating rooms worldwide.

In summary, the University of Warwick’s pioneering diamond-based magnetic field sensor leverages nitrogen vacancy centres to revolutionize cancer surgery. Miniaturized and highly sensitive, it offers a non-toxic, non-radioactive alternative to existing metastasis detection methods, poised to enhance precision in tumour resection and improve patient outcomes. This interdisciplinary breakthrough heralds a transformative application of quantum sensing, with wide-reaching implications for cancer care and beyond.

Subject of Research:
Not applicable

Article Title:
Endoscopic diamond magnetometer for cancer surgery

News Publication Date:
12-Aug-2025

Web References:
Physical Review Applied article

References:
DOI: 10.1103/znt3-988w

Image Credits:
Gavin Morley / University of Warwick

Keywords:
Diamond, Magnetometry, Cancer, Breast cancer, Health and medicine, Physical sciences

Cancer remains a leading cause of mortality worldwide, particularly gastrointestinal cancers, which are known for their aggressive nature and propensity to metastasize through the lymphatic system. The conventional methods of treating these cancers often require extensive tissue removal, resulting in significant complications for patients. The emerging technology promises a less invasive option, utilizing quantum sensors to provide real-time feedback during surgical procedures. The precision offered through this method could mean less traumatic experiences for patients and reduce their recovery time significantly.

Led by Dr. Nicole Dmochowska at UniSA’s Future Industries Institute, this project represents a collaborative effort with Ferronova, a company specializing in precision cancer surgery. Their joint venture is centered on a unique combination of the laparoscopic probe with Ferronova’s iron-oxide nanoparticle formulation, proprietary to their technology. Together, these innovations have the potential to help surgeons accurately identify cancerous lymph nodes during operations, which is a crucial step in ensuring that all cancerous tissues are removed while preserving healthy, surrounding tissue.

This partnership between academia and industry is crucial, especially considering the ambitious scale of the project valued at $405,050. The probe is engineered to work compatibly with FerroTrace, enhancing its ability to visualize cancerous nodes. Traditional lymphatic mapping often poses risks associated with radioactivity; in contrast, this quantum approach is anticipated to be safer and more effective. It signifies a shift from reliance on hazardous materials towards advanced, non-invasive technological solutions.

As technologies evolve, the possibility of improving cancer survival rates becomes more palpable. Researchers have spent over eight years refining the magnetometer probes, and the AEA Ignite Grant represents a critical milestone in their mission. The current phase focuses on developing a preclinically validated prototype that will undergo trials in large animal models. This step is vital before transitioning to human clinical trials, which could revolutionize cancer surgery forever.

The essence of this technological advancement lies in integrating quantum sensors, known for their heightened sensitivity and precision. This integration facilitates a more targeted approach, allowing surgeons to distinguish between cancerous and healthy lymphatic tissues with unprecedented clarity. Dr. Dmochowska emphasizes that this new tool will not only enhance surgical outcomes but could also fundamentally change treatment trajectories for patients diagnosed with late-stage cancers.

Previous clinical trials have demonstrated the feasibility of these quantum sensor-based systems, showcasing their potential even in complex cases such as oral cancer. As Phase-1 trials have proved successful, the researchers are ready to expand their horizons with a focus on laparoscopic applications. The goal is to miniaturize the probe, enabling its use in keyhole surgeries, which are less invasive and feature quicker recovery times for patients.

Gastrointestinal cancers require especially sensitive tools, given their propensity to spread undetected until they reach advanced stages. Providing surgeons with the means to map cancerous tissue accurately allows for more informed decisions during surgery, potentially leading to improved survival rates. As patients increasingly seek options that improve not only their survival but their quality of life, innovations such as this are becoming increasingly crucial.

Australia is positioning itself as a leader in medical science and quantum technology, with projects like this aligning with national priority areas. Dr. Benjamin Thierry, another key researcher, points out that the anticipated global market for such technologies could exceed $2 billion annually. This economic potential underscores the importance of investing in and nurturing these scientific endeavors that promise to build a future where cancer treatment is more effective and less burdensome.

As researchers and developers continue this groundbreaking work, the next stages will involve extensive testing and validation before the technology can be introduced into clinical practice. With preclinical trials expected to kick off within the year, the team remains optimistic about the outcomes and implications for future cancer treatments. These advancements bring hope not only to the scientific community but also to patients and their families worldwide, who stand to benefit from improved cancer detection and treatment modalities.

In summary, the use of quantum technologies for surgical interventions represents a leap forward in oncology. This project by UniSA and Ferronova exemplifies how interdisciplinary collaboration can lead to significant advancements in medical technology, ultimately enhancing the standard of care for cancer patients. As the landscape of medicine continues to evolve, innovations like these will be essential in shaping future therapies aimed at combating one of the most persistent challenges in healthcare.

Subject of Research: Quantum technology in cancer surgery
Article Title: Revolutionary advancements in cancer surgery from Australian research
News Publication Date: October 2023
Web References: University of South Australia, Ferronova, AEA Ignite Grant
References: N/A
Image Credits: University of South Australia

Keywords: Cancer research, Surgical procedures, Gastrointestinal neoplasms, Cancer patients, Quantum technology.